Related Experiment Videos
[Haematopoietic growth factors and solid tumors]
1CRLC Val d'Aurelle, Parc Euromédecine, Montpellier, France.
La Revue De Medecine Interne
|January 1, 1997
Summary
Hematopoietic growth factors like G-CSF, GM-CSF, and erythropoietin aid cell differentiation and treat chemotherapy side effects. They reduce febrile neutropenia and anemia, improving patient outcomes during cancer treatment.
Area of Science:
- Biochemistry
- Cell Biology
- Hematology
Context:
- Hematopoietic growth factors are key to developing diverse blood cell types.
- Recombinant versions of G-CSF, GM-CSF, and erythropoietin are clinically available.
- These factors regulate granulocytic, monocytic, and red blood cell production.
Purpose:
- To review the clinical applications of G-CSF, GM-CSF, and erythropoietin.
- To discuss their role in managing chemotherapy-induced side effects.
- To inform clinical practice regarding their prophylactic and therapeutic use.
Summary:
- G-CSF and GM-CSF reduce febrile neutropenia incidence and duration, especially in high-risk patients.
- Prophylactic use is considered for patients with >40% risk of febrile neutropenia.
- Erythropoietin treats chemotherapy-associated anemia, reducing transfusion needs.
- These factors shorten neutropenia in patients undergoing high-dose chemotherapy with autologous bone marrow support.
Impact:
- Improved management of chemotherapy side effects, potentially allowing for dose-intensity maintenance.
- Reduced incidence of serious infections like febrile neutropenia.
- Decreased need for blood transfusions in anemic cancer patients.
- Enhanced patient tolerance of cancer therapies.